Skip to main content
. 2024 Feb 2;17(2):sfae018. doi: 10.1093/ckj/sfae018

Figure 2:

Figure 2:

Changes in kidney graft function from baseline after GLP-1RAs treatment in KTRs. (A) eGFR presented on a scale ranging from −4 to 4 ml/min/1.73 m2. (B) Creatinine presented on a scale ranging from −2 to 2 mg/dl. (C) UPCR presented on a scale ranging from −8 to 8 g/g. Studies are identified by the name of the first author and the year of publication. SMDs were determined using the random effects model.